ArticleDiscover oncology2026
A multi-algorithm machine learning framework identifies FGD5, LRRC36, C8B, and MYOC as novel diagnostic biomarkers in lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) is the most common subtype of lung cancer and exhibits complex heterogeneity. Despite extensive research on driver gene mutations such as in EGFR and TP53, resistance mechanisms and co-mutations underscore the need to elucidate the molecular mechanisms of LUAD and to discover novel biomarkers for personalized treatment.
methodsWe integrated transcriptomic data from 1398 samples (1160 LUAD and 238 normal tissues) obtained from the GEO and TCGA databases. Analytical procedures included differential expression, functional enrichment (GO/KEGG/GSEA), and immune cell infiltration assessment. We applied 113 machine learning algorithms to identify core genes and develop a diagnostic model. The relationship between core gene expression and prognosis was assessed using TCGA data, and downregulation of these genes was experimentally verified by RT-PCR in A549 and Beas-2B cell lines.
resultsOur analysis revealed significant enrichment of the “cytoskeleton in muscle cells” pathway and activation of pyrimidine metabolism in LUAD. Immune profiling showed reduced proportions of monocytes and resting mast cells. We identified four core genes—FGD5, LRRC36, C8B, and MYOC—that were consistently downregulated in LUAD. A diagnostic model based on these genes demonstrated strong predictive performance, and low expression of each core gene was correlated with poor patient prognosis.Multivariate Cox regression confirmed their status as independent prognostic factors.
conclusionsThis study identifies FGD5, LRRC36, C8B, and MYOC as novel core genes and independent prognostic biomarkers in LUAD, and underscores the potential role of the “cytoskeleton in muscle cells” pathway. Our multi-faceted strategy provides new insights into LUAD pathogenesis and yields promising biomarker candidates for improving clinical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.